• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Athira Pharma Inc (NQ: ATHA )

    3.320 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 500
    Open 3.320
    Bid (Size) 3.150 (20)
    Ask (Size) 3.500 (1)
    Prev. Close 3.320
    Today's Range 3.320 - 3.320
    52wk Range 1.330 - 4.298
    Shares Outstanding 38,054,583
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
    ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +14.88%
    +14.88%
    1 Month
    +0.30%
    +0.30%
    3 Month
    +29.69%
    +29.69%
    6 Month
    -15.09%
    -15.09%
    1 Year
    +43.10%
    +43.10%

    More News

    Read More
    Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming June Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
    From Athira Pharma, Inc.
    Via GlobeNewswire
    ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming May Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    From Athira Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Sidoti Events, LLC's Virtual December Small-Cap Conference
    Via ACCESSWIRE
    These biotechs targeting multiple neurodegenerative diseases
    Via MarketBeat
    Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.